https://doi.org/10.4081/hmr.v3i3.566

Brazilian experience using high dose sequential followed by autologous hematopoietic stem cell transplantation for malignant lymphomas

Vol. 3 No. 3: 7th Meeting New Insights in Hematology Venice, Italy, 26-29 April 2009
Published: June 12, 2009
Abstract Views: 197
PDF: 140
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

BKL Duarte
support@pagepress.org
AC Vigorito
FJP Aranha
R Baldissera
ECM Miranda
IL Lorand-Metze
KB Pagnano
CA De Souza
The therapeutic of malignant lymphomas has undergone several advances through the last decades. Despite these advances, the management of relapsed and resistant patients with malignant lymphomas using conventional chemotherapy is disappointing. While patients with Hodgkin’s lymphoma (HL) have a favorable outcome when treated with regimens such as ABVD, MOPPABV and BEACOPP, with complete remission (CR) rates as high as 95%, and cure rates of 60- 85%.1,2 Some patients with advanced disease and poor prognostic factors have a poor outcome, with disease free survival (DFS) of about 10%.3-5

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Duarte, B., Vigorito, A., Aranha, F., Baldissera, R., Miranda, E., Lorand-Metze, I., Pagnano, K., & De Souza, C. (2009). Brazilian experience using high dose sequential followed by autologous hematopoietic stem cell transplantation for malignant lymphomas. Hematology Meeting Reports (formerly Haematologica Reports), 3(3). https://doi.org/10.4081/hmr.v3i3.566
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).